Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
- Registration Number
- NCT03150576
- Brief Summary
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with olaparib an inhibitor of the PARP enzyme (PARPi).
- Detailed Description
Randomised, phase II/III 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA.
Disease under investigation: Breast Cancer
Purpose of clinical trial: To establish if the addition of olaparib to neoadjuvant platinum-based chemotherapy for Triple Negative Breast Cancer (TNBC) and/or germline BRCA (gBRCA) breast cancer is safe and improves efficacy.
Trial Design: Open label, randomised, 3-stage Phase II/III
Sample Size: Minimum of 780 patients (including at least 220 gBRCA patients equally allocated to the control and the selected research arm).
Non Investigational Medicinal Products: Prophylactic granulocyte-colony stimulating factor (G-CSF) to be given as per local practice and 3 cycles of anthracyclines as per local practice.
Treatment period: A minimum of 21 weeks of chemotherapy followed by surgery.
Procedures: Screening \& enrolment
Eligible patients with early breast cancer will be registered and consented for screening:
BRCA mutation test Tumour Infiltrating Lymphocytes(TILs) score Cytokeratin 5/6 (CK5/6), Epidermal Growth Factor Receptor (EGFR) +/-, Androgen Receptor (AR) status by Immunohistochemistry (IHC).
Standard assessment prior to chemotherapy Standard staging to exclude metastatic disease. When eligibility is confirmed, patients will be randomised via a web-based central system which will allocate each patient a unique randomisation number associated with one of the treatment arms.
PARTNERing Pathway - For those patients who still have residual disease after receiving neoadjuvant chemotherapy +/- olaparib there is the opportunity to be screened to a sub-study to receive a further two cycles of chemotherapy consisting of Duralumab and AZD6738.
End of Trial: For patients, the end of trial is after the last follow-up visit or contact with the research team planned 10 years after surgery.
Procedures for safety monitoring during trial: Pharmacovigilance will be performed by the PARTNER Trial Office. Also, the Trial Management Group and the Independent Data and Safety Monitoring Committee will regularly review the patient safety data.
Criteria for discontinuation of trial treatment on safety grounds:
Severe toxicity or inter-current illness, requiring cessation in the judgement of patient's clinician.
Patient within 4 weeks has not recovered from toxicity to an extent that allows further treatment.
Patient unable to comply with trial procedures. Disease progression while on trial treatment. Patient becomes pregnant.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 780
- Aged between 16 and 70.
- Written informed consent, willing and able to comply with the Protocol for the duration of the trial including undergoing treatment and scheduled visits and examinations.
- Histologically confirmed invasive breast cancer.
- ER-negative*, and HER2-negative** breast cancer (TNBC). Patients will be eligible with any PR status but PR expression must be scored.
OR
- Germline BRCA (gBRCA) mutation positive, HER2 negative, and PgR / ER of any status.
- T1, T2 or T3 tumours.
- T4 tumour of any size with direct extension to (a) chest wall or (b) skin. OR Inflammatory carcinoma with tumour of any size. OR
Other Locally Advanced Disease:
- Involvement of ipsilateral large or fixed axillary lymph nodes, or infra or supraclavicular nodes (>10mm diameter or clinical N2 or N3) and primary breast tumour of any diameter.
- Involvement of ipsilateral large or fixed axillary lymph nodes, or infra or supraclavicular nodes (>10mm diameter, or clinical N2 or N3), without a primary breast tumour identified, the presence of breast cancer in a Lymph Node (LN) must be histopathologically confirmed by LN biopsy.
OR
Multifocal tumour:
- with at least one tumour with a size>10mm.
- Patients with bilateral disease are eligible to enter the trial provided that both breast disease meets the above criteria.
- Be fit to receive the trial chemotherapy regimen in the opinion of the responsible clinician:
Adequate bone marrow, hepatic, and renal function. ECOG performance status of 0, or 1.
- Treatment should be commenced within 6 weeks of the diagnostic biopsy. In uncommon circumstances, where medically acceptable, treatment is permitted to start within a maximum of 9 weeks of the diagnostic biopsy.
- Availability of the Tumour Infiltrating Lymphocytes score is required.
- Availability of CK 5/6 and EGFR +/- Androgen Receptor IHC score.
- Availability of slides and paraffin embedded tissue blocks from pre-chemotherapy core biopsy and from primary surgical resection is required.
- Women of child-bearing potential (WCBP), defined as not surgically sterilized or not post-menopausal for at least 24 consecutive months if age ≤55 year or 12 months if age >55 years, must have a negative serum or urine pregnancy test within 14 days prior to randomisation.
- All WCBP and all sexually active male patients as well as their partners must be aware that they should not conceive during the treatment period and therefore should routinely use effective forms of contraception, throughout their participation in the trial and for at least 6 months after the last dose of trial treatment. Please follow the olaparib contraception guidelines.
- T0 tumour in absence of axillary node >10mm.
- TNBC with a non-basal phenotype which strongly expresses Androgen Receptor.
- Previous or concomitant chemotherapy or biological agents used for the treatment of cancer in the last 5 years.
- Malignancy within the last 5 years except: adequately treated non-melanoma skin cancer; curatively treated in situ cancer of the cervix; ductal carcinoma in situ (DCIS); Stage 1, grade 1 endometrial carcinoma; or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years.
- Patients with myelodysplastic syndrome/acute myeloid leukaemia.
- Evidence of distant metastasis apparent prior to randomisation.
- Patients with uncontrolled seizures.
- Pre-existing sensory or motor neuropathy of CTCAE v4.03, grade ≥2.
- Concomitant use of known potent CYP3A4 inhibitors and inducers. Consider wash-out periods.
- Pregnant or breast feeding women.
- Not suitable for neoadjuvant chemotherapy in the opinion of the responsible clinician.
- Major surgery within 14 days of starting trial treatment and patients must have recovered from any effects of any major surgery.
- Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment or follow-up. For example:
Evidence of severe or uncontrolled cardiac disease Uncontrolled ventricular arrhythmia Recent myocardial infarction (within 12 months) Active infection including Hepatitis B, Hepatitis C and Human Immunodeficiency virus (HIV). Screening for chronic conditions is not required.
- ECG with mean resting QTc >470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.
- Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication
- Known hypersensitivity to olaparib, carboplatin, paclitaxel or their excipients (including cremophor).
- Whole blood transfusions in the last 120 days prior to blood sampling for BRCA test as it may interfere with the results (packed red blood cells and platelet transfusions are acceptable).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Paclitaxel and Carboplatin 4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 \& 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks Research 1 Paclitaxel and Carboplatin 4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 \& 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks Research 2 Paclitaxel and Carboplatin 4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 \& 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks Research 2 Olaparib 4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 \& 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks Research 1 Olaparib 4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 \& 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
- Primary Outcome Measures
Name Time Method Stage 1 - Number of participants with treatment-related adverse events as assessed by NCI CTCAE v4.03. 1 year - when first 25 patients in each research arm who had received at least one dose of Olaparib protocol treatment have completed their protocol treatment. Primary outcome measure - safety of the addition of olaparib to three weekly carboplatin/weekly paclitaxel chemotherapy.
Stage 2 - pCR rate and completion rate of Olaparib treatment as per protocol. 15 months - when pathological complete response (pCR) is available for 53 patients in each of two research arms. Primary outcome measure - pCR in each of the two research arms. At the end of stage 2, one of the research treatments will be dropped using the 'pick the winner' method.
Stage 3 - Efficacy analysis based on pCR at surgery. To be assessed by central review of pathology reports. 5.5 years - October 2021 approx. Primary outcome measure - pCR at surgery after neoadjuvant treatment. pCR rates after neoadjuvant chemotherapy +/- olaparib, defined as no residual invasive carcinoma within the breast (Ductal Carcinoma in situ permitted) AND no evidence of metastatic disease within the lymph nodes.
- Secondary Outcome Measures
Name Time Method pCR in breast alone Up to 2 years after last patient is randomised pCR in breast alone
pCR at surgery - assessed by review of histopathology slides Up to 2 years after last patient randomised pCR at surgery assessed by central pathology review of the diagnosis and surgery slides.
PARTNERing Pathway 2 cycles (each lasting 28 days) For those patients who still have residual disease after receiving neoadjuvant chemotherapy there is the opportunity to receive a further two cycles of Duralumab and AZD6738. Durvalumab I.V will be administered on cycle 1, day 1 and cycle 2, day 1. AZD6738 will be self administered by patients by mouth twice a day for 7 days beginning on cycle 1, day 22 and cycle 2, day 22.
Distant disease-free survival Up to 10 years after last patient is randomised Distant disease-free survival, calculated from date of randomisation to date of the first distant disease relapse or date of death from all causes, whichever occurs first.
Residual Cancer Burden (RCB) Up to 10 years after last patient is randomised Residual Cancer Burden (RCB) I-III will be assessed by central pathology review.
Breast cancer specific survival (BCSS) Up to 10 years after last patient is randomised Breast cancer specific survival (BCSS), calculated from date of randomisation to date of death from breast cancer.
Overall survival (OS) Up to 10 years after last patient is randomised Overall survival (OS), calculated from date of randomisation to date of death from all causes.
Relapse-Free Survival (RFS) Up to 10 years after last patient is randomised Relapse Free Survival (RFS), calculated from date of randomisation to date of first relapse or date of death from all causes, whichever occurs first.
Local recurrence-free survival Up to 10 years after last patient is randomised Local recurrence-free survival, calculated from date of randomisation to date of the first local recurrence or date of death from all causes, whichever occurs first.
Time to second cancer (TTSC) Up to 10 years after last patient is randomised Time to second cancer (TTSC), calculated from the date of randomisation to the date of diagnosis of second cancer.
Treatment related toxicities - as assessed by CTCAE v4.03 Up to 10 years after last patient is randomised Treatment related toxicities
Radiological response - as assessed by radiological response criteria as per RECIST v1.1 Up to 2 years after last patient is randomised Radiological response after 4th and final cycles
Quality of Life Questionnaire Up to 10 years after last patient is randomised Quality of Life (sub-study). Questionnaire to be completed by patient prior to start of treatment, following cycle 4 and cycle 7, following surgery and then annually for two years to document long-term effects on quality of life.
Trial Locations
- Locations (29)
The Christie
🇬🇧Manchester, Lancs, United Kingdom
University Hospital Ayr
🇬🇧Ayr, United Kingdom
Bedford General Hospital
🇬🇧Bedford, United Kingdom
Bristol Haematology & Cancer Centre
🇬🇧Bristol, United Kingdom
Velindre Cancer Centre
🇬🇧Cardiff, United Kingdom
Colchester General Hospital
🇬🇧Colchester, United Kingdom
Ipswich Hospital
🇬🇧Ipswich, United Kingdom
Russells Hall Hospital
🇬🇧Dudley, United Kingdom
Royal Free Hospital
🇬🇧London, United Kingdom
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
Churchill Hospital
🇬🇧Oxford, United Kingdom
Poole Hospital
🇬🇧Poole, United Kingdom
The Alexandra Hopsital
🇬🇧Redditch, United Kingdom
Worcestershire Royal Hospital
🇬🇧Worcester, United Kingdom
Queen's Hospital
🇬🇧Romford, United Kingdom
Pinderfields General Hospital
🇬🇧Wakefield, Yorkshire, United Kingdom
Basingstoke and North Hampshire Hospital
🇬🇧Basingstoke, United Kingdom
West Suffolk Hospital
🇬🇧Bury Saint Edmunds, United Kingdom
Hinchingbrooke Hospital
🇬🇧Huntingdon, United Kingdom
Royal Bournemouth Hospital
🇬🇧Bournemouth, United Kingdom
Kidderminster General Hospital
🇬🇧Kidderminster, United Kingdom
University Hospital Crosshouse
🇬🇧Kilmarnock, United Kingdom
Mount Vernon Cancer Centre
🇬🇧Northwood, United Kingdom
Peterborough City Hospital
🇬🇧Peterborough, United Kingdom
Southampton General Hospital
🇬🇧Southampton, United Kingdom
Singleton Hospital
🇬🇧Swansea, United Kingdom
Royal Hampshire County Hospital
🇬🇧Winchester, United Kingdom
Cambridge University Hospitals NHS Foundation Trust & the University of Cambridge
🇬🇧Cambridge, Cambridgeshire, United Kingdom
University College London Hospital
🇬🇧London, United Kingdom